drugset / Trial / NCT06487624
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Timeline
- Start
- 2025-04-02
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCB301 | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 0.6 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 1.2 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 2.4 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 4.8 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 9.6 mg/kg | Intravenous |
| Subject | HCB301 | Protein / enzyme biologic | 15 mg/kg | Intravenous |